NEWPORT BEACH, Calif.,
Jan. 10, 2012 /PRNewswire/ -- On
December 21, 2011 Cannabis Science,
Inc. (OTCBB:CBIS.OB) reported many critical ailments of which the
Company has identified as part of its ongoing mission to capture
the market share. One of which is Cancer with estimated Global drug
sales growth at a compounded annual rate of 12 to 15 percent,
reaching $75 to $80 billion by 2012.
Conservatively speaking, if the Company is able to capture only 1%
(one percent) of the Cancer market, it would translate to
approximately $75 (seventy five)
million in that segment alone.
If these figures are on the low-end spectrum then the Company's
Earnings Guidance on December 29,
2011 could be well under-estimated since their 2012
forecasted only $6,846,000 and
potentially $65,740,000 by 2014. It's
a bit early to tell if the Company is able to hit these numbers but
judging from their earlier successes from recent case studies, the
Company is on the right path to accomplish its goals and maybe
more.
Evidently, on two separate press releases, the Company reported
its brand extracts successful Cancer treatments as reported by
Squamous Cell Carcinoma and Skin Cancer self-medicating patients
with continued shrinking of Cancer cells.
According to the testimonials, these patients have
photo-documented dramatic results that the Company will release to
the public once treatment is completed and has been properly vetted
by clinical biopsy. The Company, in conjunction with several
Colorado-licensed dispensaries and
physicians, consults with a number of cancer patients who were
seeking to inform themselves of the current peer-reviewed
scientific literature, regarding modern and historical use of
cannabis preparations for treating cancers so that they can make
informed decisions regarding their self-directed cancer
treatment.
Cannabis Science went on to mention that it's making
cannabis-based medicines available to the public as rapidly as
possible. The Company is taking multiple approaches to
accomplishing this aim in the United
States. The science of cannabinoids has exploded over the
past decade, laying the scientific foundation for the many
medicinal uses of this unique plant. Cannabinoids are a class of
biologically active compounds produced by all vertebrates
(endocannabinoids) the Cannabis plant (phytocannabinoids), and more
recently patentable synthetic compounds produced by chemists.
Today's modern peer-reviewed science supports the many historical
uses that were discovered over thousands of years of medicinal use
by herbalists.
Also, the Company has already released its first two Cannabis
Science Brand Formulations, Cannabis Science CT-1 and Cannabis
Science MT-1. Both are now available at both Cannabis Therapeutics
and Marisol Therapeutics exclusively for Colorado State licensed medical marijuana
patients.
Cannabis Science MT-1: Produced by Marisol Therapeutics: A
family-owned shop, Marisol Therapeutics was founded to assist
medical marijuana patients in obtaining medical marijuana in
Colorado. They believe patients
have the right to safe, confidential, quality medical marijuana and
products. They recommend medical marijuana from their own
experience with unrelenting and previously untreatable pain. "We
understand, we care, we want you to heal." Marisal Therapeutics has
produced a custom blend of that is derived from their proprietary
strains that were developed over 30 years by a Native American
Vietnam veteran in order to address his medical needs. Cannabis
Science CT-1 has been analyzed and shown to be free of insecticides
and molds. The product is produced in soil under organic roof
conditions.
ADDRESS: 922 Kimble Drive, Pueblo
West, CO 81007
PHONE: 719-547-4000
EMAIL: info@marisolmed.com or http://marisolmed.com/ for more
information.
Cannabis Science CT-1: Produced by Cannabis Therapeutics was
Colorado's first dispensary.
Working with local law enforcement, state officials, legal experts,
medical physicians, and researchers, Cannabis Therapeutics sets a
standard of both safety and consistent quality to its members as
well as the community at large. Cannabis Therapeutics is a
professional medical business that employs all its policies and
regulations to ensure the most stringent adherence to the law.
Second in importance to legality is implementation of standardizing
techniques to ensure both repeatability in dosing and quality of
medicine. Cannabis Therapeutics began as an organization built by
individuals that did not receive satisfactory relief from
conventional therapies. Cannabis Therapeutics has produced a high
quality cannabis extract from a custom blend of buds hydroponically
grown medical marijuana strains. Cannabis Science CT-1 has been
analyzed and shown to be free of insecticides and molds.
ADDRESS: 907 E Fillmore St., Colorado
Springs, CO 80907
http://www.cannabistherapeutics.net/ for more information.
Please visit www.cannabisscience.com to view the "Breaking News"
of the successful results and images of the self-administered
cancer treatments.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade
medical marijuana research and development. The second formulations
will address the needs of patients choosing to use concentrated
cannabis extracts to treat their ailments. Eventually, all
Americans will have access to a safe and effective FDA approved
medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is
scientifically absurd. Cannabis medicines, with no effective lethal
dose, are far safer than aspirin, acetaminophen, and most other OTC
drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize
phytocannabinoid-based pharmaceutical products. In sum, we are
dedicated to the creation of cannabis-based medicines, both with
and without psychoactive properties, to treat disease and the
symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Act of 1934. A statement containing works
such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does
it intend to update the results of these forward-looking
statements.
SOURCE Cannabis Science, Inc.